- GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30. doi:10.1016/S2468-1253(19)30333-4.
- Singh S, Blanchard A, Walker JR, Graff LA, Miller N, Bernstein CN. Common symptoms and stressors among individuals with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2011;9(9):769–775. doi:10.1016/j.cgh.2011.05.016.
- Carson HJ, Dudley MH, Knight LD, Lingamfelter D. Psychosocial complications of Crohn’s disease and cause of death. J Forensic Sci. 2014;59(2):568–570. doi:10.1111/1556-4029.12314.
- Arp L, Jansson S, Wewer V, Burisch J. Psychiatric disorders in adult and paediatric patients with inflammatory bowel diseases—a systematic review and meta-analysis. J Crohns Colitis. 2022;16(12):1933–1945. doi:10.1093/ecco-jcc/jjac095.
- Tarar ZI, Zafar MU, Farooq U, et al. Burden of depression and anxiety among patients with inflammatory bowel disease: results of a nationwide analysis. Int J Colorectal Dis. 2022;37(2):313–321. doi:10.1007/s00384-021-04056-9.
- Martinho-Grueber M, Kapoglou I, Bravo F, et al. Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease. Eur J Gastroenterol Hepatol. 2023;35(1):21–30. doi:10.1097/MEG.0000000000002453.
- Niccum B, Moninuola O, Miller K, Khalili H. Opioid use among patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(5):895–907.e4. doi:10.1016/j.cgh.2020.08.041.
- Charilaou P, Mohapatra S, Joshi T, et al. Opioid use disorder increases 30-day readmission risk in inflammatory bowel disease hospitalizations: a nationwide matched analysis. J Crohns Colitis. 2020;14(5):636–645. doi:10.1093/ecco-jcc/jjz198.
- Targownik LE, Nugent Z, Singh H, Bugden S, Bernstein CN. The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. Am J Gastroenterol. 2014;109(10):1613–1620. doi:10.1038/ajg.2014.230.
- Patel P, Ali H, Manickam S, Pamarthy R, Fatakhova K, Rajapakse R. Substance abuse and inpatient outcomes in inflammatory bowel disease hospitalizations in the United States: a propensity matched analysis. Ann Gastroenterol. 2023;36(1):32–38. doi:10.20524/aog.2022.0767.
- Khera R, Angraal S, Couch T, et al. Adherence to methodological standards in research using the National Inpatient Sample. JAMA. 2017;318(20):2011–2018. doi:10.1001/jama.2017.17653.
- Ali H, Pamarthy R, Bolick NL, Lambert K, Naseer M. Relation between inflammatory bowel disease, depression, and inpatient outcomes in the United States. Proc (Bayl Univ Med Cent). 2022;35(3):278–283. doi:10.1080/08998280.2022.2028344.
- Gudicha DW, Schmittmann VD, Vermunt JK. Statistical power of likelihood ratio and Wald tests in latent class models with covariates. Behav Res Methods. 2017;49(5):1824–1837. doi:10.3758/s13428-016-0825-y.
- Sanford D, Thornley P, Teriaky A, Chande N, Gregor J. Opioid use is associated with decreased quality of life in patients with Crohn’s disease. Saudi J Gastroenterol. 2014;20(3):182–187. doi:10.4103/1319-3767.133020.
- Mantzouranis G, Fafliora E, Saridi M, et al. Alcohol and narcotics use in inflammatory bowel disease. Ann Gastroenterol. 2018;31(6):649–658. doi:10.20524/aog.2018.0302.
- Barnes EL. Patterns of opioid use among patients with inflammatory bowel disease: do we need better disease control or multidisciplinary interventions? Crohns Colitis 360. 2020;2(1):otaa010. doi:10.1093/crocol/otaa010.
- Kuźnicki P, Neubauer K. Emerging comorbidities in inflammatory bowel disease: eating disorders, alcohol and narcotics misuse. JCM. 2021;10(19):4623. doi:10.3390/jcm10194623.
- Ramos GP, Kane S. Alcohol use in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2021;17(5):211–225.
- Hsu TY, Shih HM, Wang YC, et al. Effect of alcoholic intoxication on the risk of inflammatory bowel disease: a nationwide retrospective cohort study. PLoS One. 2016;11(11):e0165411. doi:10.1371/journal.pone.0165411.
- Carney H, Marrie RA, Bolton JM, et al. Prevalence and risk factors of substance use disorder in inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(1):58–64. doi:10.1093/ibd/izaa014.
- Cohen-Mekelburg S, Rosenblatt R, Gold S, et al. The impact of opioid epidemic trends on hospitalised inflammatory bowel disease patients. J Crohns Colitis. 2018;12(9):1030–1035. doi:10.1093/ecco-jcc/jjy062.
- Guida L, Di Giorgio FM, Busacca A, et al. Perception of the role of food and dietary modifications in patients with inflammatory bowel disease: impact on lifestyle. Nutrients. 2021;13(3):759. doi:10.3390/nu13030759.
- Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(8):1937–1944. doi:10.1097/MIB.0000000000000832.
- Click B, Ramos Rivers C, Koutroubakis IE, et al. Demographic and clinical predictors of high healthcare use in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(6):1442–1449. doi:10.1097/MIB.0000000000000763.
- Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;156:84–89. doi:10.1016/j.drugalcdep.2015.08.035.
- Ballou S, Hirsch W, Singh P, et al. Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014. Aliment Pharmacol Ther. 2018;47(7):913–921. doi:10.1111/apt.14551.
- Siddiqui MT, Singh A, Kirby DF, Regueiro MD. Prevalence and outcomes of alcohol use disorders in patients with inflammatory bowel disease. Gastroenterology. 2021;160(6):S-57–S-58. doi:10.1016/S0016-5085(21)00882-9.
- Verma M, Horrow J, Navarro V. A Behavioral health program for alcohol use disorder, substance abuse, and depression in chronic liver disease. Hepatol Commun. 2019;3(5):646–655. doi:10.1002/hep4.1328.
- Murthy VH. Ending the opioid epidemic—a call to action. N Engl J Med. 2016;375(25):2413–2415. doi:10.1056/NEJMp1612578.
- Healthcare Cost and Utilization Project (HCUP). Content last reviewed December 2022. Agency for Healthcare Research and Quality. https://www.ahrq.gov/data/hcup/index.html.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 36, 2023 - Issue 4
Original Research: Gastroenterology
Trends in hospital admissions and mortality among inflammatory bowel disease patients with substance use disorder: a 10-year United States nationwide analysis
, MD, 
, , , MD, , , MD, , , MD, , MD, , MD, , MBBS, , MD, , MD & , MD show all
Pratik Patela Department of Gastroenterology, Mather Hospital and Hofstra University Zucker School of Medicine, Port Jefferson, New Yorkhttps://orcid.org/0000-0003-1375-8542
, MDhttps://orcid.org/0000-0003-1375-8542, Faisal Inayatb Department of Medicine, Allama Iqbal Medical College, Lahore, Punjab, PakistanCorrespondence[email protected]
https://orcid.org/0000-0001-7576-7319
, MBBShttps://orcid.org/0000-0001-7576-7319, , MD, Hassam Alid Department of Internal Medicine, East Carolina University Brody School of Medicine, Greenville, North Carolinahttps://orcid.org/0000-0001-5546-9197
, MDhttps://orcid.org/0000-0001-5546-9197, , MD, Gul Nawazf Department of Internal Medicine, Marshfield Clinic Health System, Marshfield, Wisconsinhttps://orcid.org/0000-0002-4978-4761
, MDhttps://orcid.org/0000-0002-4978-4761, , MD, , MD, , MD, , MBBS, , MD, , MD & , MD show all